Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 8;41:54. doi: 10.1186/s13046-021-02221-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — cPLA2 inhibitor increases the infiltration of proliferative activated CD4/CD8 tumor-infiltrating T lymphocytes (TILs) in TME of tumor bearing S100A7 overexpressing mice (A). Schematic diagram of CODEX workflow showing the different steps of FFPE TMAs staining (B). Seven-color image of FFPE TMA prepared from of orthotopic syngeneic breast cancer model of mS100a7a15 bi-transgenic mouse model and imaged using a 25 DNA-barcode conjugated antibodies panel. 7 colors show the following markers: red- CD8a, yellow- CD45R, cyan- CD11b, White- CD90.2, blue- CD4, magenta- CD38, and green- Ki67 (C). Heatmap showing the average strength of cell-type to cell-type interaction for different clusters of vehicle control (VC) and cPLA2 inhibitor (AF3) treated mS100a7a15 overexpression mouse model (D). t-SNE and heatmap showing the expression of different markers associated with proliferating and activated CD4+ and CD8+ T cells (E). Circos plot and, (F). heat map showing the cell interaction networks of different subsets of proliferating and activated CD4+ and CD8+ T cells in VC and AF3 treated groups. The thickness of interacting connection associates with the number of contacts, size of the node represents the number of cells per group. Scale bar in heat map showing the interaction strength of different connecting nodes (G). Spearman rho’s correlation coefficient analysis of cPLA2 mRNA (PLA2G4A) expression with infiltration level of CD4 and CD8 T cells in invasive basal-like breast cancer patients (source: TIMER2.0; http://timer.cistrome.org/)